Plain-English translation of NCT06499870 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of two medications— and —given together with radiation therapy to treat very advanced prostate cancer. works by lowering testosterone, which helps slow prostate cancer growth, while blocks how cancer cells respond to male hormones. The goal is to see if this three-part approach can prevent the cancer from coming back.
Very advanced prostate cancer is hard to treat and often comes back even after standard therapy. Doctors want to know if this medication combination, when paired with radiation, can work better at stopping the cancer long-term and improving survival.
You likely qualify if…
You likely don't qualify if…
You will take two daily pills by mouth for up to 18 months. After 4 months of medication, you'll begin radiation therapy sessions. Throughout the study, you'll have regular blood tests, imaging scans (MRI and PET scans), and possibly a biopsy. After treatment ends, you'll have follow-up visits every 3–6 months for up to 30 months to monitor your health and check if the cancer has returned.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States